BridgeBio Pharma Inc
BBIOMarket price data through November 12, 2026.
Performance
Nov 2021 – Nov 2026
Track record
How this pick has done since Benson first called it.
- Benson Return
- +155%
- How much this stock is up since Benson first picked it — measured from the price at the time of that first pick, not from today.
- First pick price
- ~$31
- Roughly what one share cost when Benson first picked this stock. This is the starting line for the Benson Return.
- Tracking since
- September 2024
- The month this stock first became a Benson pick.
- Tracking duration
- 26 months
- How long Benson has been tracking this pick.
About BridgeBio Pharma Inc
BridgeBio makes medicines for rare genetic diseases. Its star product, Attruby, is a once-a-day pill for a condition that slowly stiffens the heart. Three more medicines are now waiting on regulators for a yes or no.
The case for and against
Both sides of the story, in plain English.
- Revenue Rocket
BridgeBio brought in 353.2 million dollars last quarter, and 253.2 million of that came from its heart pill Attruby in the U.S. Attruby sales more than doubled from a year ago and grew another 31 million dollars in just three months. More doctors are picking it first for newly diagnosed patients, and a study of 2,684 patients found a 25 percent lower risk of hospital stays than with the older treatment.
- Launches Lined Up
Three new medicines have decision dates within seven months. They are November 27 for a muscle disease, February 4 for a childhood bone growth condition, and May 8 for a rare calcium disorder. With 1.5 billion dollars in the bank, the company has enough to pay for all three launches, and the sales teams are already hired.
- Losses Still Linger
The company lost only 11.6 million dollars from operations this quarter, but a one-time 75 million dollar payment from its partner Bayer helped a lot. Without that payment, the loss would have been closer to 87 million dollars. Over the past year, losses have been nearly as big as revenue.
- One Pill Show
About 72 percent of last quarter's revenue came from Attruby, and most of the rest was that one-time Bayer payment. If a rival takes share or insurers push back on price, nothing else is big enough to fill the gap yet. The three new medicines still need approval, and the first answer isn't due until November 27.
Other companies we track
How to read this page
This automated research summary uses Financial Modeling Prep market data through 2026-11-12. Model signals, scores, and risk labels can change and may be incomplete or wrong.
Want Benson to watch BBIO for you?
Get the app to follow every Benson pick live — and let Benson do the research for you.